EUVIMEDEUVIMED entdecken
Crossref

Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines

Lara Milevoj Kopcinovic, Adriana Unic, Nora Nikolac Gabaj, Marijana Miler, Alen Vrtaric, Marija Bozovic, Mario Stefanovic

Laboratory Medicine · 2024

DOI: 10.1093/labmed/lmad044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laboratory Medicine, 2024. Verfasst von Lara Milevoj Kopcinovic und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Immunoglobulin G, Immunogenicity, Vaccine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the association of immune response with vaccination adverse effects at peak anti–receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria.

Methods

Anti-RBDS1 IgG concentrations after vaccination were determined in healthy adults vaccinated with the Comirnaty, Spikevax, and Vaxzevria vaccines. The association of reactogenicity and peak antibody response after vaccination was tested.

Results

Anti-RBDS1 IgG values were significantly higher in the Comirnaty and Spikevax group, compared with the Vaxzevria group (P < .001). Fever and muscle pain were found to be significant independent predictors of peak anti-RBDS1 IgG in the Comirnaty and Spikevax groups (P = .03 and P = .02, respectively). The multivariate model, adjusted for covariates, showed that no association between reactogenicity and peak antibody concentrations was found in the Comirnaty, Spikevax, and Vaxzevria groups.

Conclusions

No association between reactogenicity and peak anti-RBDS1 IgG after vaccination with the Comirnaty, Spikevax, and Vaxzevria vaccine was found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesImmunoglobulin GImmunogenicity, VaccineAdultHumans2019-nCoV Vaccine mRNA-1273BNT162 VaccineChAdOx1 nCoV-19

Stichwörter der Autor:innen

COVID vaccineComirnatySARS-CoV-2SpikevaxVaxzevriaanti-spike antibodyreactogenicity

Substanzen

2019-nCoV Vaccine mRNA-1273BNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesImmunoglobulin G

Autor:innen und Institutionen

  • Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.
  • Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.

Zitieren

APA

Milevoj Kopcinovic, L., Unic, A., Nikolac Gabaj, N., Miler, M., Vrtaric, A., Bozovic, M., & Stefanovic, M. (2024). Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines. Laboratory Medicine. https://doi.org/10.1093/labmed/lmad044

Vancouver

Milevoj Kopcinovic L, Unic A, Nikolac Gabaj N, Miler M, Vrtaric A, Bozovic M, et al. Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines. Laboratory Medicine. 2024. doi:10.1093/labmed/lmad044

BibTeX
@article{MilevojKopcinovic2024,
  author = {Milevoj Kopcinovic, Lara and Unic, Adriana and Nikolac Gabaj, Nora and Miler, Marijana and Vrtaric, Alen and Bozovic, Marija and Stefanovic, Mario},
  title = {Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines},
  journal = {Laboratory Medicine},
  year = {2024},
  doi = {10.1093/labmed/lmad044}
}
Kostenlos starten →